• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    12/4/24 4:05:33 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGNE alert in real time by email
    SC 13D/A 1 p24-3466sc13da.htm BEIGENE, LTD.
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 5)*
     

    BeiGene, Ltd.

    (Name of Issuer)
     

    Ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)
     

    07725L102

    (CUSIP Number)
     

    Richard A. Hornung

    HHLR Advisors, Ltd.

    Office #122, Windward 3 Building, Regatta Office Park

    West Bay Road, Grand Cayman

    Cayman Islands, KY1-9006

     

    With a copy to:

     

    Eleazer N. Klein, Esq.

    Adriana F. Schwartz, Esq.

    Schulte Roth & Zabel LLP

    919 Third Avenue

    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    December 2, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

     

    (Page 1 of 5 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

      

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 07725L102SCHEDULE 13D/APage 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    HHLR Advisors, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF (See Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    125,045,741 Ordinary Shares*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    125,045,741 Ordinary Shares*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    125,045,741 Ordinary Shares*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.0%

    14

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of (i) 111,597,423 ordinary shares held by a fund managed by HHLR (as defined below), of which 36,011,300 ordinary shares are held in the form of 2,770,100 ADSs and (ii) 13,448,318 ordinary shares held by a fund managed by HIM (as defined below), of which 13,445,978 ordinary shares are held in the form of 1,034,306 ADSs. HHLR and HIM are under common control and share certain policies, personnel and resources.

     

     

    CUSIP No. 07725L102SCHEDULE 13D/APage 3 of 5 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Hillhouse Investment Management, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF (See Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    125,045,741 Ordinary Shares*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    125,045,741 Ordinary Shares*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    125,045,741 Ordinary Shares*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.0%

    14

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of (i) 111,597,423 ordinary shares held by a fund managed by HHLR, of which 36,011,300 ordinary shares are held in the form of 2,770,100 ADSs and (ii) 13,448,318 ordinary shares held by a fund managed by HIM, of which 13,445,978 ordinary shares are held in the form of 1,034,306 ADSs. HHLR and HIM are under common control and share certain policies, personnel and resources.

     

     

    CUSIP No. 07725L102SCHEDULE 13D/APage 4 of 5 Pages

     

    This Amendment No. 5 (“Amendment No. 5”) amends the statement on Schedule 13D previously filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) (as previously filed and amended and amended further hereby, the “Schedule 13D”) with respect to the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”) of BeiGene, Ltd., an exempted Cayman Islands company (the “Issuer”). Capitalized terms used herein and not otherwise defined in this Amendment No. 5 have the meanings set forth in the Schedule 13D. This Amendment No. 5 amends Items 5 (a)-(c) as set forth below.

     

    Item 5. Interest in Securities of the Issuer
       
    Items 5 (a)-(c) of the Schedule 13D are hereby amended and restated as follows:
     
    (a) See rows (11) and (13) of the cover pages to this Schedule 13D/A for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each Reporting Person.  The percentage used in this Schedule 13D/A is calculated based upon 1,386,034,320 Ordinary Shares outstanding as of November 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the Securities and Exchange Commission on November 12, 2024.
       
    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c)

    On December 2, 2024, HHLR Fund sold 1,372,500 ADSs pursuant to a block trade with Goldman Sachs & Co. LLC at a price of $200 per ADS.

       

     

     

    CUSIP No. 07725L102SCHEDULE 13D/APage 5 of 5 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this Schedule 13D/A is true, complete and correct.

     

    Date: December 4, 2024

     

      HHLR Advisors, LTD.
       
       
       
     

    /s/ Audrey Woon

     

    Name: Audrey Woon

    Title: Chief Compliance Officer

     

      HillHOUSE INVESTMENT MANAGEMENT, LTD.
       
       
       
     

    /s/ Audrey Woon

     

    Name: Audrey Woon

    Title: Chief Compliance Officer

     

     

    Get the next $BGNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGNE

    DatePrice TargetRatingAnalyst
    12/3/2024$300.00Overweight
    Morgan Stanley
    9/18/2024$288.00Mkt Outperform
    JMP Securities
    2/6/2024$185.00Overweight
    JP Morgan
    9/12/2023$259.00Outperform
    Macquarie
    8/17/2023$287.00Buy
    Jefferies
    7/17/2023$275.00Buy
    Citigroup
    6/30/2023$335.00 → $196.00Outperform → Mkt Perform
    Bernstein
    1/12/2023$308.00Buy
    Daiwa Securities
    More analyst ratings

    $BGNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

      Positive opinion for first-line treatment of extensive-stage small cell lung cancer based on results of RATIONALE-312 study demonstrating statistically significant overall survival benefit for TEVIMBRA in combination with chemotherapy BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lu

      3/31/25 6:00:00 AM ET
      $BGNE
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

      New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA approval for TEVIMBRA in 2024 BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors e

      12/27/24 6:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

      BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to "ONC" on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. "As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative h

      12/23/24 6:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on BeiGene with a new price target

      Morgan Stanley resumed coverage of BeiGene with a rating of Overweight and set a new price target of $300.00

      12/3/24 8:35:59 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on BeiGene with a new price target

      JMP Securities initiated coverage of BeiGene with a rating of Mkt Outperform and set a new price target of $288.00

      9/18/24 7:31:13 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan resumed coverage on BeiGene with a new price target

      JP Morgan resumed coverage of BeiGene with a rating of Overweight and set a new price target of $185.00

      2/6/24 7:59:18 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    SEC Filings

    See more
    • BeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BeiGene, Ltd. (0001651308) (Filer)

      12/23/24 6:05:32 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - BeiGene, Ltd. (0001651308) (Filer)

      12/10/24 6:02:43 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by BeiGene Ltd.

      144 - BeiGene, Ltd. (0001651308) (Subject)

      12/9/24 9:48:25 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

      SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

      12/10/24 9:30:34 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

      SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

      12/4/24 4:05:33 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

      SC 13D/A - BeiGene, Ltd. (0001651308) (Filed by)

      10/31/24 6:29:37 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Leadership Updates

    Live Leadership Updates

    See more
    • Labcorp CFO Glenn Eisenberg Announces Plans to Retire

      Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

      11/19/24 7:00:00 AM ET
      $BGNE
      $LH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

      BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board's Audit Committee, effective September 27, 2024. "We are fortunate to welcome Shalini to the Board of Directors at this pivotal moment of growth," said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. "The Board is looking forward to collaborating with Shalini, whose extensive experience in leading innovative global pharmaceutical companies will be invaluable as we enter new markets, advance our pipeline of groundbreaking cancer therapies, and embark on a transformative growth phase. Her financial

      9/26/24 6:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Announces Updates to Commercial Leadership Team

      BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. "We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "Matt's management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies." Mr. Shaulis is a global commercial executive with ov

      9/9/24 7:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Financials

    Live finance-specific insights

    See more

    $BGNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors

      BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support Investigational New Drug filing BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global biotechnology company, and DualityBio, a next-generation ADC company, today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors. "With one of the industry's leading global oncology research teams, we are investing in highly impactful therapeutic modalities such as ADCs that complement our dynam

      7/10/23 7:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene's BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH

       Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual Meeting BRUKINSA demonstrated superiority to IMBRUVICA in both PFS and Overall Response Rate with fewer cardiac events BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))) a global biotechnology company, today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA® as compared to IMBRUVICA® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic

      12/13/22 10:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's Early Development Pipeline and Research on August 25, 2021

      BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160))), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it will host an investor conference call and webcast on Wednesday, August 25, 2021, at 9:30 a.m. ET to discuss the Company's early development pipeline and research. A live webcast of the conference call can be accessed from the investors section of BeiGene's website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available after the event for 90 days. About BeiGene BeiGene is a global, science-driven biotechnology company

      8/16/21 7:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Oyler John exercised 1,300,000 units of Ordinary Shares at a strike of $0.50, increasing direct ownership by 77% to 2,978,833 units (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      12/17/24 5:02:43 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chair, Scientific Advisory Brd Wang Xiaodong sold $7,805,106 worth of American Depositary Shares (41,760 units at $186.90) and exercised 41,760 units of American Depositary Shares at a strike of $6.50 (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      12/12/24 5:18:09 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Baker Bros. Advisors Lp sold $194,200,043 worth of American Depositary Shares (1,037,017 units at $187.27) (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      12/10/24 9:25:48 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care